Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novacyt ( (FR:ALNOV) ) has issued an announcement.
Novacyt S.A. reported an unaudited trading update for the first half of 2025, with group revenue expected to be around £9.8 million, a slight decrease from the previous year. Despite this, the company saw growth in its clinical segment and NIPT technologies, with significant demand in the APAC region. Novacyt remains debt-free with a strong cash position, supporting its path to EBITDA profitability. The launch of LightBench® Discover positions Novacyt at the forefront of genomic research, marking a significant milestone post-restructuring.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. It develops, manufactures, and commercializes molecular assays and instrumentation to deliver end-to-end solutions across sectors like human health, animal health, and environmental. The company operates in three business segments: Clinical, Instrumentation, and Research Use Only, and has a commercial presence in over 65 countries.
Learn more about ALNOV stock on TipRanks’ Stock Analysis page.